Hints and tips:
Related Special Reports
...Bristol Myers Squibb said on Wednesday that chief executive Giovanni Caforio would step down as chief executive on November 1 and be replaced by chief commercialisation officer Christopher Boerner....
...Giovanni Caforio also said low pricing for medicines purchased by the NHS from pharmaceutical companies was a major issue that threatened the UK’s ambition to become a leader in the life sciences industry...
...Giovanni Caforio, chief executive of the US drugmaker, told the Financial Times it was reviewing its portfolio and expected that some drug candidates would not be funded as a result of reforms in the administration...
...“We have made decisions to stop programmes,” Giovanni Caforio, BMS chief executive and chair, told the Financial Times in July....
...Giovanni Caforio, BMS chief executive, said 2021 was a pivotal year for the company, as it achieved significant regulatory and clinical milestones that had positioned it to successfully renew its portfolio...
...“Our industry depends on intellectual property protection in order to invest in R&D and make the investments needed to address crises like Covid,” Giovanni Caforio told the FT US Pharma and Biotech Summit...
...Sinema received several large donations from healthcare and pharmaceutical industry bosses in the third quarter, including Bristol-Myers Squibb chair and chief executive Giovanni Caforio, Eli Lilly chief...
...“Our industry depends on intellectual property protection in order to invest in R&D and make the investments needed to address crises like Covid,” Giovanni Caforio said....
...Giovanni Caforio, Bristol-Myers Squibb’s chief executive, told the Financial Times that MyoKardia’s drug mavacamten had the potential to be a “multibillion-dollar franchise in the second half of the decade...
...Giovanni Caforio, chairman and chief executive, said it would move forward with the deal....
...“This agreement represents an important step toward completing our pending merger with Celgene,” said Giovanni Caforio, chairman and chief executive of Bristol-Myers....
...Caforio said in a statement....
...“We are beginning 2019 with good momentum in our current business, with Opdivo and Eliquis continuing as strong and growing franchises,” said chief executive Giovanni Caforio....
...However Giovanni Caforio, chief executive of BMS, told the Financial Times it had done “really good due diligence on the pipeline of Celgene....
...In an interview, however, Giovanni Caforio, chief executive of BMS, robustly defended a merger that he said created “immense value for [BMS] shareholders” by bringing together two businesses with complementary...
...Giovanni Caforio, chief executive of Bristol-Myers Squibb, hails “unprecedented progress” with immunotherapies, but concedes the next step, which he describes as finding “intelligent combinations”, has not...
...Dr Giovanni Caforio, chairman and chief executive officer, said:....
...BMS chief executive Giovanni Caforio credited “strong commercial execution and solid trends across our products and geographies” for the earnings and profit beat....
...Dr Giovanni Caforio, chief executive officer of Bristol-Myers, said: While we are disappointed CheckMate -026 did not meet its primary endpoint in this broad patient population, we remain committed to improving...
...In a statement this week to the Financial Times, Giovanni Caforio, Bristol-Myers’ chief executive, said: “While acknowledging the competitive landscape continues to evolve, we believe the combination of...
...Dr Giovanni Caforio, chief executive of Bristol-Myers, said he was “disappointed” by the failure but remained “committed to improving patient outcomes”....
International Edition